Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Mar;77(6):992–997. doi: 10.1038/bjc.1998.163

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

S Viviani 1, E Camerini 1, V Bonfante 1, A Santoro 1, M Balzarotti 1, M Fornier 1, L Devizzi 1, P Verderio 1, P Valagussa 1, G Bonadonna 1
PMCID: PMC2150083  PMID: 9528846

Abstract

The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean+/-standard error) were significantly higher in patients than in 65 healthy control subjects (1842+/-129 U ml(-1) vs 420+/-10 U ml(-10, P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635+/-19 U ml(-1) vs 1795+/-122 U ml(-1), P=0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent.

Full text

PDF
993

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banks R. E., Patel P. M., Selby P. J. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer. 1995 Apr;71(4):655–659. doi: 10.1038/bjc.1995.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blay J. Y., Farcet J. P., Lavaud A., Radoux D., Chouaïb S. Serum concentrations of cytokines in patients with Hodgkin's disease. Eur J Cancer. 1994;30A(3):321–324. doi: 10.1016/0959-8049(94)90249-6. [DOI] [PubMed] [Google Scholar]
  3. Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features. Am J Clin Pathol. 1989 Aug;92(2):186–191. doi: 10.1093/ajcp/92.2.186. [DOI] [PubMed] [Google Scholar]
  4. Clerici M., Ferrario E., Trabattoni D., Viviani S., Bonfanti V., Venzon D. J., Clerici E., Shearer G. M., Villa M. L. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer. 1994;30A(10):1464–1470. doi: 10.1016/0959-8049(94)00305-o. [DOI] [PubMed] [Google Scholar]
  5. Durrleman S., Simon R. Flexible regression models with cubic splines. Stat Med. 1989 May;8(5):551–561. doi: 10.1002/sim.4780080504. [DOI] [PubMed] [Google Scholar]
  6. Enblad G., Sundström C., Gronowitz S., Glimelius B. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis. Ann Oncol. 1995 Jan;6(1):65–70. doi: 10.1093/oxfordjournals.annonc.a059044. [DOI] [PubMed] [Google Scholar]
  7. Gause A., Roschansky V., Tschiersch A., Smith K., Hasenclever D., Schmits R., Diehl V., Pfreundschuh M. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol. 1991 Feb;2 (Suppl 2):43–47. doi: 10.1007/978-1-4899-7305-4_7. [DOI] [PubMed] [Google Scholar]
  8. Gooding R., Riches P., Dadian G., Moore J., Gore M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer. 1995 Aug;72(2):452–455. doi: 10.1038/bjc.1995.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gorschlüter M., Bohlen H., Hasenclever D., Diehl V., Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995 May;6(5):477–482. doi: 10.1093/oxfordjournals.annonc.a059218. [DOI] [PubMed] [Google Scholar]
  10. Grimfors G., Andersson B., Tullgren O., Giscombe R., Holm G., Johansson B., Björkholm M. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease. Br J Haematol. 1992 Feb;80(2):166–171. doi: 10.1111/j.1365-2141.1992.tb08895.x. [DOI] [PubMed] [Google Scholar]
  11. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol Today. 1992 Jun;13(6):198–200. doi: 10.1016/0167-5699(92)90153-X. [DOI] [PubMed] [Google Scholar]
  12. Hsu P. L., Hsu S. M. Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2. Am J Pathol. 1989 Oct;135(4):735–745. [PMC free article] [PubMed] [Google Scholar]
  13. Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987 Dec;45(3):440–446. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  14. Kretschmer C., Jones D. B., Morrison K., Schlüter C., Feist W., Ulmer A. J., Arnoldi J., Matthes J., Diamantstein T., Flad H. D. Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease. Am J Pathol. 1990 Aug;137(2):341–351. [PMC free article] [PubMed] [Google Scholar]
  15. Kurzrock R., Redman J., Cabanillas F., Jones D., Rothberg J., Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993 May 1;53(9):2118–2122. [PubMed] [Google Scholar]
  16. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630. [DOI] [PubMed] [Google Scholar]
  17. Matsuda T., Hirano T. Interleukin 6 (IL-6). Biotherapy. 1990;2(4):363–373. doi: 10.1007/BF02170085. [DOI] [PubMed] [Google Scholar]
  18. Motoi T., Uchiyama T., Hori T., Itoh K., Uchino H., Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood. 1989 Aug 15;74(3):1052–1057. [PubMed] [Google Scholar]
  19. Pfreundschuh M., Pohl C., Berenbeck C., Schroeder J., Jung W., Schmits R., Tschiersch A., Diehl V., Gause A. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer. 1990 May 15;45(5):869–874. doi: 10.1002/ijc.2910450515. [DOI] [PubMed] [Google Scholar]
  20. Pizzolo G., Chilosi M., Vinante F., Dazzi F., Lestani M., Perona G., Benedetti F., Todeschini G., Vincenzi C., Trentin L. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer. 1987 Apr;55(4):427–428. doi: 10.1038/bjc.1987.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Proctor S. J., Taylor P., Mackie M. J., Donnan P., Boys R., Lennard A., Prescott R. J. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma. 1992;7 (Suppl):17–20. doi: 10.3109/10428199209061558. [DOI] [PubMed] [Google Scholar]
  22. Pui C. H., Ip S. H., Iflah S., Behm F. G., Grose B. H., Dodge R. K., Crist W. M., Furman W. L., Murphy S. B., Rivera G. K. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988 Apr;71(4):1135–1137. [PubMed] [Google Scholar]
  23. Pui C. H., Ip S. H., Thompson E., Dodge R. K., Brown M., Wilimas J., Carrabis S., Kung P., Berard C. W., Crist W. M. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood. 1989 Jan;73(1):209–213. [PubMed] [Google Scholar]
  24. Romagnani S., Ferrini P. L., Ricci M. The immune derangement in Hodgkin's disease. Semin Hematol. 1985 Jan;22(1):41–55. [PubMed] [Google Scholar]
  25. Rovelli F., Lissoni P., Crispino S., Barni S., Fumagalli G., Paolorossi F., Tancini G. Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori. 1988 Dec 31;74(6):633–637. doi: 10.1177/030089168807400603. [DOI] [PubMed] [Google Scholar]
  26. Rubin L. A., Jay G., Nelson D. L. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol. 1986 Dec 15;137(12):3841–3844. [PubMed] [Google Scholar]
  27. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  28. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  29. Schornagel J. H., van der Vegt S., Verweij J., de Graeff A., Dullemond-Westland A., van Deijk W. A., ten Bokkel Huinink W. W. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol. 1992 Jul;3(7):549–552. doi: 10.1093/oxfordjournals.annonc.a058258. [DOI] [PubMed] [Google Scholar]
  30. Semenzato G., Foa R., Agostini C., Zambello R., Trentin L., Vinante F., Benedetti F., Chilosi M., Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood. 1987 Aug;70(2):396–400. [PubMed] [Google Scholar]
  31. Specht L., Nordentoft A. M., Cold S., Clausen N. T., Nissen N. I. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988 Apr 15;61(8):1719–1727. doi: 10.1002/1097-0142(19880415)61:8<1719::aid-cncr2820610834>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  32. Steis R. G., Marcon L., Clark J., Urba W., Longo D. L., Nelson D. L., Maluish A. E. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988 May;71(5):1304–1309. [PubMed] [Google Scholar]
  33. Wanebo H. J., Pace R., Hargett S., Katz D., Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer. 1986 Feb 1;57(3):656–662. doi: 10.1002/1097-0142(19860201)57:3<656::aid-cncr2820570343>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES